Michael C. Barnes, JD, Principal Attorney at Sequel Legal and Chairman of the Center for U.S. Policy, will speak at the American Pharmacists Association (APhA) 2021 Annual Meeting on Monday, March 15. Mr. Barnes will co-present the session, entitled “Don’t ‘Just Say No’: Preventing Diversion and Addressing Medical Needs,” with Jake Nichols, PharmD, CEO of Professional Recovery Resources. Mr. Barnes will provide an overview of federal and state […]
The Drug Enforcement Administration (DEA) has temporarily relaxed the federal requirements for prescribing buprenorphine for opioid use disorder (OUD) via telemedicine during the COVID-19 public health emergency. As a general rule, the federal Controlled Substances Act (CSA) requires a valid prescription before a controlled prescription medication may be delivered, distributed, or dispensed by means of […]
The COVID-19 outbreak has presented extraordinary challenges in prescribing buprenorphine to new and existing patients with opioid use disorder (OUD). Telemedicine presents an opportunity to reach these patients and promote continuity of care; however, rapidly evolving circumstances have caused confusion among many practitioners as to their rights and obligations under federal law when prescribing controlled […]
Four Washington, DC attorneys have been selected to speak or moderate at the Rx Drug Abuse & Heroin Summit in Nashville next month. Stacey Worthy, JD will join two nationally renowned addiction physicians in presenting, “Duking It Out Over Electronic Data-Sharing: Law, Ethics, and Best Practices in Addiction Medicine” on Monday, April 13: Privacy regulations […]
On February 26, 2020, DEA issued a proposed rule titled Registration Requirements for Narcotic Treatment Programs with Mobile Components. The proposed rule would waive the requirement of a separate registration for opioid treatment programs (OTPs) that utilize a mobile component. The Controlled Substances Act (CSA) generally requires, with certain exceptions, all persons who dispense controlled […]